Mast Cell Tumor

Mast cell tumor (MCT) is the most common malignant cutaneous neoplasm in dogs and the second most common in cats. It arises from neoplastic transformation of mast cells, which are granulated immune cells of the myeloid lineage that reside in tissues, particularly skin and mucosa. MCTs exhibit a wide spectrum of biological behavior, ranging from benign, slowly growing nodules to highly aggressive, metastatic, and life-threatening malignancies. Surgical excision remains the cornerstone of treatment, with the goal of achieving complete histological margins. The clinical approach is guided by tumor grade, stage, and location, with adjunctive therapies (radiation, chemotherapy, targeted therapy) employed for high-grade or incompletely excised tumors. In veterinary surgical oncology, MCTs are classified histologically (Patnaik and Kiupel grading systems) and staged according to the World Health Organization (WHO) TNM system. The disease is characterized by local recurrence, potential for regional lymph node metastasis, and systemic spread to spleen, liver, and bone marrow in aggressive forms. Surgical management requires meticulous planning, including wide margins, sentinel lymph node evaluation, and reconstruction techniques to achieve functional and cosmetic outcomes.

The exact etiology of mast cell tumors is multifactorial and not fully understood. Genetic mutations, particularly in the c-KIT proto-oncogene, play a central role. Activating mutations in exon 11 (internal tandem duplications) and exon 8 lead to constitutive activation of the KIT receptor tyrosine kinase, promoting uncontrolled mast cell proliferation and survival. These mutations are found in approximately 20-30% of canine MCTs and are associated with higher grade and worse prognosis. Other potential etiological factors include chronic inflammation, environmental carcinogens, and viral agents, though evidence is limited. In cats, a viral etiology (feline leukemia virus) has been suggested but not confirmed. Breed-specific genetic predispositions indicate a hereditary component, particularly in Boxers, Boston Terriers, and Pugs, where MCTs are common but often low-grade. In contrast, Shar-Peis and Bull Mastiffs may have a genetic predisposition to high-grade tumors. Hormonal influences have been proposed but not substantiated. The role of growth factors, such as stem cell factor (SCF), is critical, as SCF binding to KIT is essential for mast cell development and survival. Dysregulation of this pathway is a key driver of tumorigenesis.

Mast cell tumors are the most common malignant skin tumor in dogs, accounting for 16-21% of all cutaneous neoplasms. They are less common in cats, representing 8-21% of feline skin tumors. In dogs, the median age at diagnosis is 8-9 years, but tumors can occur in young dogs. Certain breeds are overrepresented: Boxers, Boston Terriers, Labrador Retrievers, Beagles, Schnauzers, and Staffordshire Bull Terriers. Boxers and Pugs often develop multiple low-grade tumors, while Shar-Peis and Bull Mastiffs tend to have high-grade tumors with a poorer prognosis. No consistent sex predilection is reported, though some studies suggest a slight male predominance. In cats, Siamese and related breeds are predisposed, and the median age is 8-10 years. The incidence of MCTs appears to be increasing, possibly due to improved diagnostic awareness. Anatomically, MCTs can occur anywhere on the body, but common sites include the trunk (50-60%), extremities (25-40%), and head/neck (10-15%). In dogs, MCTs on the prepuce, scrotum, and digits are associated with a worse prognosis. In cats, the cutaneous form is often benign, but the visceral form (splenic and intestinal) is highly malignant. The biological behavior varies by breed and histologic grade, with high-grade tumors having a higher metastatic rate (50-80%) compared to low-grade tumors (less than 10%).

Mast cell tumors arise from neoplastic mast cells that accumulate in tissues due to uncontrolled proliferation and resistance to apoptosis. The key molecular event is dysregulation of the KIT receptor tyrosine kinase. In normal mast cells, KIT activation by stem cell factor (SCF) promotes survival, proliferation, and differentiation. Mutations in c-KIT lead to ligand-independent activation, causing continuous signaling through downstream pathways such as PI3K/AKT and RAS/MAPK, which drive cell cycle progression and inhibit apoptosis. The tumor microenvironment, including fibroblasts, endothelial cells, and inflammatory cells, supports tumor growth and angiogenesis. Mast cells contain cytoplasmic granules rich in histamine, heparin, proteases, and cytokines. When degranulated, these mediators cause local inflammation, pruritus, and ulceration. Histamine release can lead to gastric hyperacidity and gastrointestinal ulceration, a paraneoplastic syndrome. Heparin can cause bleeding tendencies. The tumor's growth pattern is typically dermal and subcutaneous, with infiltration into surrounding tissues. High-grade tumors exhibit marked cellular pleomorphism, high mitotic index, and deep invasion. Metastasis occurs primarily via the lymphatic system to regional lymph nodes, then to spleen, liver, and bone marrow. The histological grade (Patnaik or Kiupel) correlates with metastatic potential: low-grade tumors have a low risk, while high-grade tumors have a high risk. The Kiupel grading system, which uses mitotic count and cellular morphology, is more reproducible and prognostically accurate than the older Patnaik system.

Predisposing factors for mast cell tumors include genetic, breed, and environmental influences. Breed predisposition is significant, with certain breeds having a higher incidence and distinct tumor behavior. Boxers and Pugs often develop multiple low-grade tumors, while Shar-Peis and Bull Mastiffs are prone to high-grade tumors with a poorer prognosis. Age is a factor, with older dogs (median 8-9 years) more commonly affected. Sex is not a consistent risk factor, though some studies report a slight male predominance. Chronic skin inflammation or irritation may contribute to tumor development, but evidence is anecdotal. Exposure to environmental carcinogens, such as pesticides or tobacco smoke, has been suggested but not proven. Genetic mutations, particularly in c-KIT, are the most significant intrinsic factor. The presence of c-KIT mutations is associated with higher-grade tumors and worse outcomes. In cats, Siamese and related breeds are predisposed, and the risk increases with age. Obesity and diet have not been directly linked to MCT development. Prior history of MCT increases the risk of developing additional tumors, as some dogs develop multiple independent MCTs. Immunosuppression or immune dysregulation may also play a role, as mast cells are part of the immune system.

Clinical signs of mast cell tumors vary depending on tumor location, grade, and stage. The most common presentation is a solitary, raised, firm to fluctuant mass in the skin or subcutaneous tissue. The mass may be alopecic, erythematous, and ulcerated. Pruritus and pain are common due to histamine release. The tumor may fluctuate in size, enlarging and shrinking due to degranulation and edema. In some cases, the tumor is soft and cystic. Multiple tumors may be present, especially in certain breeds. Systemic signs can occur due to histamine release, including vomiting, diarrhea, inappetence, and lethargy. Gastric ulceration may lead to melena or hematemesis. In advanced stages, signs of metastasis include lymphadenopathy, hepatosplenomegaly, and bone marrow suppression (anemia, thrombocytopenia, leukopenia). Cats with cutaneous MCTs often present with a similar solitary mass, but they may also have a military form with multiple small nodules. Visceral MCTs in cats cause vomiting, diarrhea, weight loss, and abdominal distension. On physical examination, the mass should be assessed for size, location, mobility, and involvement of underlying tissues. Regional lymph nodes should be palpated for enlargement. A thorough abdominal palpation may reveal organomegaly. The clinical stage is determined by the WHO TNM system: T (tumor size and invasion), N (lymph node metastasis), and M (distant metastasis).

Differential diagnoses for mast cell tumors include other cutaneous and subcutaneous masses. Key differentials include: 1) Lipoma - a benign fatty tumor, soft, mobile, and non-painful; cytology shows mature adipocytes. 2) Sebaceous adenoma - a benign proliferation of sebaceous glands, often wart-like; cytology shows clusters of sebocytes. 3) Histiocytoma - a benign epidermal Langerhans cell tumor, common in young dogs, rapidly growing, dome-shaped; cytology shows round cells with moderate cytoplasm. 4) Plasmacytoma - a plasma cell tumor, often solitary, cytology shows plasma cells with eccentric nuclei. 5) Lymphoma - cutaneous lymphoma can present as a mass or plaque; cytology shows large lymphoid cells. 6) Soft tissue sarcoma - a malignant mesenchymal tumor, firm, infiltrative; cytology shows spindle cells. 7) Melanoma - a malignant melanocytic tumor, often pigmented; cytology shows melanin granules. 8) Squamous cell carcinoma - a malignant epithelial tumor, often ulcerated; cytology shows keratinocytes with atypia. 9) Transmissible venereal tumor (TVT) - a round cell tumor, typically on external genitalia; cytology shows round cells with vacuolated cytoplasm. 10) Granulomatous inflammation - due to fungal or bacterial infection; cytology shows mixed inflammatory cells. Definitive diagnosis requires cytology or histopathology, with special stains (toluidine blue, Giemsa) to identify mast cell granules.

The diagnostic algorithm for mast cell tumors begins with a thorough history and physical examination, including palpation of the mass and regional lymph nodes. Fine-needle aspiration (FNA) of the mass is the first step; cytology can confirm the presence of mast cells, which appear as round cells with purple granules on Diff-Quik or Wright-Giemsa stain. If cytology is inconclusive, an incisional or excisional biopsy is performed for histopathology. Histological grading (Patnaik or Kiupel) is essential for prognosis and treatment planning. Staging is recommended for high-grade tumors or if metastasis is suspected. Staging includes: 1) FNA of regional lymph nodes, even if normal-sized, to detect micrometastasis. 2) Complete blood count (CBC) to evaluate for anemia, thrombocytopenia, or eosinophilia. 3) Serum biochemistry profile to assess liver and kidney function. 4) Abdominal ultrasound to evaluate for splenic, hepatic, or other abdominal metastasis. 5) Thoracic radiographs to check for pulmonary metastasis (rare but possible). 6) Buffy coat smear or bone marrow aspiration if systemic mastocytosis is suspected. Advanced imaging (CT or MRI) may be used for surgical planning, especially for tumors in complex locations. Sentinel lymph node mapping using lymphoscintigraphy or dye injection is increasingly recommended to identify the draining lymph node for biopsy. The diagnostic workup should be completed before surgical excision to guide the extent of surgery and need for adjunctive therapy.

Laboratory findings in mast cell tumors are often non-specific but can provide valuable information. A complete blood count (CBC) may reveal anemia (due to chronic disease or gastrointestinal bleeding), thrombocytopenia (due to heparin release or bone marrow infiltration), and eosinophilia (due to histamine release). A buffy coat smear may show circulating mast cells in cases of systemic mastocytosis. Serum biochemistry profile may show elevated liver enzymes (ALT, ALP) if hepatic metastasis or paraneoplastic syndrome is present. Hypoalbuminemia may occur due to gastrointestinal loss. Coagulation abnormalities, such as prolonged bleeding time, may be due to heparin release. In cats, feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) testing may be recommended. Urinalysis is usually unremarkable. Inflammatory biomarkers, such as C-reactive protein (CRP), may be elevated but are not specific. Synovial fluid analysis is not typically performed unless there is joint involvement. For surgical planning, a coagulation panel (PT, aPTT, platelet count) is recommended, especially if the tumor is large or ulcerated. Histamine levels in plasma or urine can be measured but are not routinely used. The most important laboratory finding is the histopathological grade, which is determined by examination of the biopsy specimen.

Imaging plays a crucial role in staging and surgical planning for mast cell tumors. Thoracic radiographs (three views) are recommended to evaluate for pulmonary metastasis, though MCTs rarely metastasize to the lungs. Abdominal ultrasound is essential to assess the spleen, liver, and abdominal lymph nodes for metastasis. Ultrasonographic findings may include splenic nodules, hepatomegaly, or lymphadenopathy. Ultrasound-guided FNA of suspicious organs can confirm metastasis. Computed tomography (CT) is increasingly used for surgical planning, especially for tumors in complex anatomical regions (e.g., head, neck, perineum). CT provides detailed information about tumor extent, invasion into underlying tissues, and regional lymph node involvement. CT can also be used for radiation therapy planning. Magnetic resonance imaging (MRI) is superior for soft tissue contrast and is useful for evaluating tumors near the spinal cord or in the brain, though MCTs rarely affect these areas. Lymphoscintigraphy or sentinel lymph node mapping using technetium-99m or methylene blue dye can identify the sentinel lymph node for biopsy. In cases of suspected bone involvement, radiographs or CT of the affected area may be indicated. Imaging findings should be correlated with cytology or histopathology for definitive diagnosis.

Cytology and histopathology are the cornerstones of mast cell tumor diagnosis and grading. Fine-needle aspiration (FNA) cytology is a rapid, minimally invasive technique that can provide a presumptive diagnosis. On cytological examination, mast cells appear as round cells with abundant cytoplasm containing purple to magenta granules (metachromatic) when stained with Diff-Quik or Wright-Giemsa. The granules may obscure the nucleus. Eosinophils are often present. Cytology can differentiate MCT from other round cell tumors (lymphoma, plasmacytoma, histiocytoma) but cannot reliably grade the tumor. Histopathology is required for grading. An incisional biopsy (punch or wedge) is preferred for large tumors to guide treatment, while excisional biopsy is both diagnostic and therapeutic for small tumors. Histological grading is performed using the Patnaik system (grades I, II, III) or the Kiupel system (low-grade vs. high-grade). The Patnaik system evaluates cellularity, cell morphology, mitotic index, and depth of invasion. Grade I (well-differentiated) tumors have a low mitotic index (<1 per high-power field) and are benign. Grade III (poorly differentiated) tumors have a high mitotic index (>3 per HPF) and are malignant. Grade II tumors are intermediate. The Kiupel system is simpler and more reproducible: low-grade tumors have a mitotic count of ≤4 per 10 HPF and no multinucleated cells or bizarre nuclei; high-grade tumors have a mitotic count of >4 per 10 HPF or have multinucleated cells or bizarre nuclei. Kiupel grading is now preferred due to better prognostic correlation. Additionally, immunohistochemistry for KIT expression patterns (membranous vs. cytoplasmic) and c-KIT mutation analysis can provide prognostic information. Surgical margins should be evaluated for completeness; margins of 2-3 cm are recommended for low-grade tumors, while high-grade tumors may require wider margins.

Treatment of mast cell tumors is primarily surgical, with the goal of complete excision. The recommended surgical margin is 2-3 cm lateral and one fascial plane deep for low-grade tumors, and wider margins (3-5 cm) for high-grade tumors. However, the margin should be tailored to the tumor grade and location. For tumors on extremities, amputation may be necessary if wide excision is not feasible. For tumors on the trunk, primary closure or reconstructive techniques (skin flaps, skin grafts) may be required. Preoperative preparation includes administration of antihistamines (e.g., diphenhydramine 2 mg/kg PO q8h) and H2 blockers (e.g., famotidine 0.5 mg/kg IV or PO q12h) to prevent histamine-induced complications. If the tumor is large or ulcerated, broad-spectrum antibiotics (e.g., cefazolin 22 mg/kg IV at induction) are indicated. Surgical technique involves careful dissection to avoid tumor rupture, as degranulation can cause local inflammation and systemic effects. The tumor should be removed en bloc with a margin of normal tissue. The surgical site should be closed with tension-relieving techniques if needed. Sentinel lymph node biopsy is recommended for high-grade tumors or if the lymph node is enlarged. If metastasis is confirmed, the lymph node should be excised. Adjunctive therapies include radiation therapy for incompletely excised tumors or high-grade tumors with a high risk of local recurrence. Radiation therapy is effective in controlling local disease. Chemotherapy (e.g., vinblastine 2 mg/m² IV q1-2 weeks, with prednisone 1-2 mg/kg PO q24h) is used for high-grade tumors, metastatic disease, or incompletely excised tumors with high-grade features. Targeted therapy with tyrosine kinase inhibitors (e.g., toceranib phosphate 2.75 mg/kg PO q48h) is effective for tumors with c-KIT mutations. For cats, surgical excision is also the primary treatment, and the prognosis is generally good for cutaneous MCTs. Visceral MCTs in cats are treated with surgery (splenectomy) and chemotherapy, but the prognosis is poor.

The prognosis for mast cell tumors varies widely depending on several factors, including histological grade, clinical stage, and treatment. Low-grade (Patnaik grade I or Kiupel low-grade) tumors have an excellent prognosis, with a median survival time of over 2 years and a low metastatic rate (<10%). Complete surgical excision is often curative. Intermediate-grade (Patnaik grade II) tumors have a variable prognosis, with a median survival time of 1-2 years. High-grade (Patnaik grade III or Kiupel high-grade) tumors have a poor prognosis, with a median survival time of 4-6 months despite aggressive treatment. The metastatic rate for high-grade tumors is 50-80%. Negative prognostic indicators include high mitotic index, presence of c-KIT mutations, cytoplasmic KIT staining pattern, tumor location (prepuce, scrotum, digits), and advanced clinical stage (lymph node or distant metastasis). Incompletely excised tumors have a higher risk of local recurrence, but radiation therapy can improve local control. The overall recurrence rate after incomplete excision is 20-30%, but with radiation therapy, the local control rate is >90%. For cats, cutaneous MCTs have a good prognosis, with a median survival time of 1-2 years, but visceral MCTs have a poor prognosis, with a median survival time of 3-6 months. The prognosis for dogs with multiple MCTs is similar to that for solitary tumors if each tumor is treated appropriately.

Postoperative follow-up for mast cell tumors is essential to monitor for recurrence and metastasis. The surgical site should be examined for signs of dehiscence, infection, or seroma formation. Sutures or staples are typically removed 10-14 days after surgery. Histopathology results should be reviewed to confirm complete excision and grade. For low-grade tumors with complete excision, re-examination every 3-6 months for the first year, then annually, is recommended. For high-grade tumors or incompletely excised tumors, more frequent monitoring is needed. A complete physical examination, including palpation of the surgical site and regional lymph nodes, should be performed at each visit. Thoracic radiographs and abdominal ultrasound may be repeated every 3-6 months for high-grade tumors to screen for metastasis. If the patient received radiation therapy, follow-up with the radiation oncologist is necessary. If chemotherapy or targeted therapy is administered, regular blood work (CBC, biochemistry) is required to monitor for adverse effects. Owners should be educated to monitor for new masses, as dogs with MCTs are at risk for developing additional tumors. Any new mass should be aspirated and evaluated. Long-term follow-up is recommended for at least 2 years after diagnosis, as late recurrence or metastasis can occur.

Clinical pearls: 1) Always perform FNA of any new skin mass before surgical excision; cytology can diagnose MCT quickly. 2) Administer antihistamines and H2 blockers preoperatively to prevent histamine-related complications. 3) For tumors on extremities, consider a tourniquet to reduce bleeding and tumor cell dissemination. 4) Use a surgical marker to plan margins before incision, and include the biopsy tract in the excision. 5) For large tumors, consider a two-stage approach: incisional biopsy first, then definitive surgery based on grade. 6) Sentinel lymph node biopsy is crucial for high-grade tumors; use lymphoscintigraphy or dye injection to identify the node. 7) If the tumor is close to a vital structure, such as the eye or anus, consider radiation therapy instead of aggressive surgery. 8) For cats, cutaneous MCTs are often benign, but visceral MCTs are malignant; stage accordingly. Pitfalls: 1) Do not excise a MCT without prior staging, as high-grade tumors may have metastasized. 2) Avoid tumor rupture during surgery, as it can cause local recurrence and systemic histamine release. 3) Do not rely solely on Patnaik grading; use Kiupel grading for better prognostic accuracy. 4) Incomplete excision of high-grade tumors is associated with a high recurrence rate; consider re-excision or radiation therapy. 5) Do not overlook the possibility of multiple MCTs; perform a thorough skin examination. 6) Avoid using corticosteroids alone for treatment, as they are not curative. 7) Do not delay surgery for high-grade tumors, as they can metastasize quickly. 8) Monitor for gastrointestinal ulceration postoperatively, especially in dogs with large tumors.

Perioperative drug protocols for mast cell tumors are based on Plumb's Veterinary Drug Handbook. Preoperative: Diphenhydramine (2 mg/kg PO) or chlorpheniramine (0.4 mg/kg PO) administered 30-60 minutes before surgery to block histamine H1 receptors. Famotidine (0.5 mg/kg IV or PO) or omeprazole (1 mg/kg PO) to reduce gastric acid secretion. Prophylactic antibiotics: Cefazolin (22 mg/kg IV) at induction, repeated every 90 minutes during surgery. Postoperative analgesia: Opioids such as hydromorphone (0.05-0.1 mg/kg IV or IM q4-6h) or buprenorphine (0.01-0.02 mg/kg IV or IM q6-8h). Non-steroidal anti-inflammatory drugs (NSAIDs) such as carprofen (2.2 mg/kg PO q12h) or meloxicam (0.1 mg/kg PO q24h) for 3-5 days, but avoid in patients with renal or hepatic disease. Local anesthesia: Lidocaine (2 mg/kg) or bupivacaine (1-2 mg/kg) as a local block or wound infusion. For chemotherapy: Vinblastine (2 mg/m² IV) every 1-2 weeks, with prednisone (1-2 mg/kg PO q24h) for 3-4 weeks, then taper. Toceranib phosphate (2.75 mg/kg PO q48h) for c-KIT mutant tumors. For rescue therapy, lomustine (60-90 mg/m² PO) every 3 weeks may be used. Antiemetics: Maropitant (1 mg/kg SC q24h) for histamine-induced vomiting. Gastroprotectants: Sucralfate (0.5-1 g PO q8h) for gastric ulceration. In cats, use lower doses and avoid NSAIDs. Always adjust dosages based on renal and hepatic function.

Landmark studies and consensus guidelines have shaped the management of mast cell tumors. The Patnaik grading system (1984) was the first to correlate histologic features with prognosis, but its reproducibility is limited. The Kiupel grading system (2011) was developed to improve prognostic accuracy and is now recommended by the ACVS and other consensus panels. Studies have shown that Kiupel grading is more reproducible and better predicts survival. The role of c-KIT mutations was established by London et al. (1999), who found that mutations in exon 11 are associated with higher grade and worse prognosis. Toceranib phosphate, a tyrosine kinase inhibitor, was approved for the treatment of MCTs based on a pivotal study by London et al. (2009), which demonstrated a 42% overall response rate. Surgical margins have been evaluated in several studies; a 2-3 cm margin is generally recommended, but a study by Simpson et al. (2004) found that a 2 cm margin was sufficient for low-grade tumors. Sentinel lymph node mapping has been shown to improve staging accuracy, as reported by Worley (2014). Radiation therapy is effective for incompletely excised tumors, with local control rates exceeding 90% (Farese et al., 2004). Chemotherapy with vinblastine and prednisone is commonly used for high-grade tumors, but a meta-analysis by Vail et al. (2017) found limited evidence of survival benefit. The ACVS and Veterinary Society of Surgical Oncology have published consensus statements on the diagnosis and treatment of MCTs, emphasizing the importance of histologic grading, staging, and multimodal therapy. Future directions include the use of molecular biomarkers and targeted therapies.